Overview

Pharmacodynamic Effects of a Free-Fatty Acid Formulation of Omega-3 Pentaenoic Acid in Adults With Hypertriglyceridemia

Status:
Active, not recruiting
Trial end date:
2021-06-01
Target enrollment:
Participant gender:
Summary
Pharmacodynamic effects of MAT9001 compared to Vascepa in adults with hypertriglyceridemia
Phase:
Phase 2
Details
Lead Sponsor:
Matinas BioPharma Nanotechnologies, Inc.
Collaborators:
Matinas Biopharma, Inc
MB Clinical Research and Consulting LLC
Treatments:
Eicosapentaenoic acid ethyl ester